| 标题 |
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet. Oncology 作者:Kudo M; Abou-Alfa GK; Ren Z; Heo J; Lencioni R; et al 出版日期:2026/09/01 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)